Neuphoria's Net Loss Skyrockets to $9.9M Amid R&D Surge

TL;DR

**NEUP is burning cash at an alarming rate; expect further dilution or a significant financing event soon.**

AI Summary

Neuphoria Therapeutics Inc. (NEUP) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $9.91 million, a substantial rise from the $0.80 million net loss in the same period of 2024. This was primarily driven by a sharp increase in research and development expenses, which more than doubled to $3.79 million from $1.90 million year-over-year, and a substantial loss of $4.37 million on fair value adjustments compared to a gain of $2.87 million in the prior year. The company's cash and cash equivalents decreased to $13.65 million as of September 30, 2025, from $14.21 million on June 30, 2025. Total liabilities increased to $14.83 million from $9.59 million, largely due to a significant increase in accompanying warrants liability to $8.09 million from $3.70 million. Neuphoria continues to operate without product revenues and has an accumulated deficit of $188.3 million, raising substantial doubt about its ability to continue as a going concern without additional financing.

Why It Matters

Neuphoria's escalating net loss and dwindling cash position signal a critical juncture for investors, highlighting the urgent need for additional capital. The substantial increase in R&D spending, while potentially advancing its BNC210 PTSD candidate and Merck-partnered drugs, is rapidly consuming resources. This financial strain could impact the company's ability to fund ongoing clinical trials and compete effectively in the highly capital-intensive neuropsychiatric drug development space, potentially delaying or halting promising therapies for patients. Employees face uncertainty regarding job security, and the broader market will watch closely for signs of successful financing or strategic partnerships.

Risk Assessment

Risk Level: high — The company incurred a net loss of $9.91 million for the three months ended September 30, 2025, and has an accumulated deficit of $188.3 million. Cash and cash equivalents decreased to $13.65 million, and the company explicitly states there is 'substantial doubt about the Company's ability to continue as a going concern within one year' without additional financing.

Analyst Insight

Investors should exercise extreme caution and consider the high risk of further dilution given the company's stated going concern issues and significant cash burn. Monitor closely for any announcements regarding new financing rounds or strategic partnerships, as these will be critical for the company's survival.

Financial Highlights

debt To Equity

1.19

revenue

$0

operating Margin

N/A

total Assets

$27.34M

total Debt

$14.83M

net Income

-$9.91M

eps

-$4.41

gross Margin

N/A

cash Position

$13.65M

revenue Growth

N/A

Key Numbers

• $9.91M — Net Loss (Increased from $0.80M in Q3 2024, indicating significant financial deterioration.)
• $3.79M — R&D Expenses (More than doubled from $1.90M in Q3 2024, driving increased operating costs.)
• $4.37M — Loss on Fair Value Adjustments (Shifted from a $2.87M gain in Q3 2024, significantly impacting other income/loss.)
• $13.65M — Cash and Cash Equivalents (Decreased from $14.21M at June 30, 2025, highlighting ongoing cash burn.)
• $188.3M — Accumulated Deficit (Indicates a long history of losses and the need for substantial future profitability.)
• $8.09M — Accompanying Warrants Liability (Increased significantly from $3.70M at June 30, 2025, contributing to total liabilities.)
• 2,357,613 — Common Shares Outstanding (Increased from 1,978,460 at June 30, 2025, indicating recent equity issuance.)
• $4.41 — Net Loss Per Share (Increased from $0.62 in Q3 2024, reflecting higher losses and share count.)

Key Players & Entities

• Neuphoria Therapeutics Inc. (company) — registrant and clinical-stage biotechnology company
• Merck & Co., Inc. (company) — strategic partner with two drugs in early-stage clinical trials
• BNC210 (product) — lead drug candidate for PTSD
• $9.91 million (dollar_amount) — net loss for the three months ended September 30, 2025
• $0.80 million (dollar_amount) — net loss for the three months ended September 30, 2024
• $3.79 million (dollar_amount) — research and development expenses for Q3 2025
• $1.90 million (dollar_amount) — research and development expenses for Q3 2024
• $13.65 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $188.3 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $8.09 million (dollar_amount) — accompanying warrants liability as of September 30, 2025

FAQ

Risk Factors

• Substantial doubt about going concern [high — financial]: Neuphoria Therapeutics Inc. has an accumulated deficit of $188.3 million and has not generated product revenues. The company's net loss for the three months ended September 30, 2025, was $9.91 million, a significant increase from $0.80 million in the prior year. This raises substantial doubt about its ability to continue as a going concern without additional financing.
• Increasing cash burn and liabilities [high — financial]: Cash and cash equivalents decreased to $13.65 million as of September 30, 2025, from $14.21 million on June 30, 2025. Total liabilities increased to $14.83 million from $9.59 million, primarily due to a jump in accompanying warrants liability to $8.09 million from $3.70 million. This trend indicates a worsening financial position.
• Surge in R&D expenses [medium — operational]: Research and development expenses more than doubled to $3.79 million for the three months ended September 30, 2025, from $1.90 million in the same period of 2024. This significant increase in operating costs is a primary driver of the widening net loss.
• Adverse fair value adjustments [medium — financial]: The company experienced a loss of $4.37 million on fair value adjustments for the three months ended September 30, 2025, a stark contrast to a gain of $2.87 million in the prior year. This volatility significantly impacted the net loss.
• Dilution from share issuance [medium — financial]: The number of common shares outstanding increased to 2,357,613 as of September 30, 2025, from 1,978,460 on June 30, 2025. This increase in share count, coupled with higher net losses, led to a substantial rise in net loss per share to $4.41 from $0.62 year-over-year.

Industry Context

Neuphoria Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focused on drug development. This industry is characterized by long development cycles, high R&D costs, significant regulatory hurdles, and the need for substantial funding to advance pipeline candidates through clinical trials and to market. Success often depends on innovation, intellectual property, and the ability to secure partnerships or further investment.

Regulatory Implications

As a biotechnology company, Neuphoria is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet efficacy or safety standards, or changes in regulatory pathways can significantly impact development timelines and costs. Compliance with evolving regulations is crucial for advancing drug candidates.

What Investors Should Do

1. Monitor cash burn rate closely: With cash decreasing and liabilities rising, investors should track the company's ability to manage its operating expenses and secure future funding.
2. Evaluate R&D pipeline progress: The significant increase in R&D spending necessitates close monitoring of clinical trial progress and potential milestones to justify the investment.
3. Assess future financing needs: Given the substantial accumulated deficit and ongoing losses, investors should anticipate potential equity raises or debt financing, which could lead to dilution.
4. Analyze fair value adjustment volatility: Understand the drivers behind the significant loss on fair value adjustments, as this can introduce considerable volatility to earnings.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported a net loss of $9.91 million, a significant increase from the prior year, with rising R&D expenses and a large loss on fair value adjustments. Cash and cash equivalents decreased, while total liabilities increased substantially.
• 2025-06-30: End of Q2 2025 — Reported cash and cash equivalents of $14.21 million and total liabilities of $9.59 million, serving as the prior period benchmark for the Q3 2025 balance sheet changes.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $0.80 million and R&D expenses of $1.90 million, providing a key year-over-year comparison point for the current period's financial deterioration.

Glossary

Accumulated deficit

The cumulative net losses of a company since its inception that have not been offset by profits. (Indicates Neuphoria's long history of operating at a loss, totaling $188.3 million, highlighting the need for future profitability or significant funding.)

Accompanying warrants liability

A liability recorded for warrants issued alongside other securities, such as debt or equity, which may be exercised in the future. (This liability increased significantly to $8.09 million from $3.70 million, contributing substantially to the rise in total liabilities and potentially indicating future dilution if exercised.)

Fair value adjustments

Changes in the reported value of assets or liabilities to reflect their current market value, which can result in gains or losses. (Neuphoria experienced a substantial loss of $4.37 million from these adjustments in Q3 2025, a reversal from a gain in the prior year, significantly impacting net income.)

Going concern

An accounting assumption that a business will continue to operate for the foreseeable future without the threat of liquidation. (The company's financial condition raises substantial doubt about its ability to continue as a going concern, a critical warning for investors regarding its viability.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Neuphoria Therapeutics Inc. has experienced a significant financial downturn. Net loss widened dramatically from $0.80 million to $9.91 million, driven by a more than doubling of R&D expenses to $3.79 million and a substantial swing from a gain to a loss on fair value adjustments. While cash reserves saw a slight decrease, total liabilities more than doubled, largely due to an increase in accompanying warrants liability, indicating increased financial risk and potential dilution.

Key Financial Figures

• $0.00001 — nge on which registered Common Stock, $0.00001 par value per share NEUP The Nasdaq

Filing Documents

• neup-20250930.htm (10-Q) — 1259KB
• neup-ex31_1.htm (EX-31.1) — 20KB
• neup-ex31_2.htm (EX-31.2) — 20KB
• neup-ex32_1.htm (EX-32.1) — 11KB
• neup-ex32_2.htm (EX-32.2) — 13KB
• 0001193125-25-281579.txt ( ) — 5851KB
• neup-20250930.xsd (EX-101.SCH) — 985KB
• neup-20250930_htm.xml (XML) — 807KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) 2 Condensed Consolidated Statement of Changes in Shareholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 PART II. OTHER INFORMATION 21 Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5. Other Information 24 Item 6. Exhibits 24

Signatures

Signatures 26 i Basis of Presentation Neuphoria Therapeutics Inc. is a Delaware corporation ("Neuphoria") listed on the Nasdaq Global Market. We were formally known as Bionomics Limited ("Bionomics") an Australian company that on October 1, 2024 entered into a Scheme Implementation Agreement with Neuphoria to re-domicile from Australia to the State of Delaware pursuant to a Scheme of Arrangement under Australian law. On December 23, 2024, the re-domiciliation of Bionomics was implemented and effectuated in accordance with the Scheme Implementation Agreement, as amended. As a result, (i) holders of ordinary shares of Bionomics received one share of our common stock for every 2,160 ordinary shares of Bionomics held on the Scheme record date; (ii) holders of Bionomics' American Depositary Shares ("ADS") with each ADS representing 180 ordinary shares of Bionomics, received one share of Neuphoria's common stock for every 12 ADSs held on the Scheme record date; and (iii) we became the successor issuer to Bionomics. Prior to our redomiciliation, since July 1, 2024, we had been reporting as a domestic U.S. issuer on SEC Forms 10-K, 10-Q, and 8-K. The terms "we," "our," "us" and the "Company" in this Quarterly Report on Form 10-Q refer to Neuphoria Therapeutics Inc. and its consolidated subsidiaries after December 23, 2024 and Bionomics and its consolidated subsidiaries on and prior to December 23, 2024, unless otherwise specified. When we refer to "you," we mean the potential holders of the applicable series of securities: "shares" or "ordinary shares" refers to our ordinary shares prior to December 23, 2024; shares of common stock refers to our common stock, par value $0.00001 per share beginning December 24, 2024; "ADSs" refers to American Depositary Shares, each of which represented 180 ordinary shares prior to December 23, 2024; and "ADRs" refers to American Depositary Receipts, which evidence the ADSs. We use our registered and unregistered trademar

—F INANCIAL INFORMATION

PART I—F INANCIAL INFORMATION

Cond ensed Consolidated Financial Statements

Item 1. Cond ensed Consolidated Financial Statements. Neuphoria Therapeutics Inc. Condensed Cons olidated Balance Sheets (Unaudited) September 30, June 30, 2025 2025 Assets Current assets: Cash and cash equivalents $ 13,649,638 $ 14,210,745 Accounts receivable, non-trade 1,758 11,948 Restricted cash 78,564 77,945 Prepaid insurance expense 222,319 740,193 Total current assets 13,952,279 15,040,831 Property and equipment, net 2,573 2,771 Intangible assets, net 4,639,108 4,804,791 Operating lease right-of-use assets 75,219 102,612 Goodwill 8,674,734 8,638,609 Total assets $ 27,343,913 $ 28,589,614 Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 1,370,728 $ 1,154,369 Accrued expenses and other current liabilities 3,668,338 2,950,077 Operating lease liability 85,210 116,314 Total current liabilities 5,124,276 4,220,760 Contingent consideration 1,156,912 1,169,675 Deferred tax liability 460,320 495,113 Accompanying warrants liability 8,092,218 3,701,492 Total liabilities 14,833,726 9,587,040 Commitments and contingencies (Note 16) Shareholders' equity: Common stock, $ 0.00001 par value, 2,357,613 and 1,978,460 shares issued and outstanding at September 30, 2025 and June 30, 2025, respectively 23 19 Additional paid-in capital, net of subscription receivable 203,559,216 200,194,324 Accumulated other comprehensive loss, net of tax ( 2,795,845 ) ( 2,845,066 ) Accumulated deficit ( 188,253,207 ) ( 178,346,703 ) Total shareholders' equity 12,510,187 19,002,574 Total liabilities and shareholders' equity $ 27,343,913 $ 28,589,614 The accompanying notes are an integral part of the unaudited condensed consolidated financial statements. 1 Neuphoria Therapeutics Inc. Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudi

View Full Filing

View this 10-Q filing on SEC EDGAR